HZHuifang Zhou

Huifang Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Huifang Zhou has a total of 107 co-authors. Here are the top co-authors by number of shared publications:

  • Haiqing Qian

    Department of Reproduction Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine Suzhou Jiangsu China

    3 shared publications
  • Hua Feng

    Nanjing Univ Chinese Med, Clin Med Coll 1, Nanjing, Peoples R China

    3 shared publications
  • Jing Jin

    Affiliated Hospital of Nanjing University of Chinese Medicine (Jiangsu Province Hospital of Traditional Chinese Medicine), Nanjing, China

    3 shared publications
  • Lihong Wang

    Department of Reproduction, Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Zhangjiagang, Jiangsu, China

    3 shared publications
  • Yinyin Ding

    Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China

    3 shared publications
  • Yujie Shang

    Nanjing Univ Chinese Med, Clin Med Coll 1, Nanjing, Peoples R China

    3 shared publications

Latest Publications

  • Nuangong Tiaojing Formula ameliorates luteal phase defect by restoring ovarian-uterine axis function via regulating inflammatory-apoptotic cascade

    by Mingqian Hao, Xi Xue, Yinjia Li, Xingcheng Wu, Yaqin Gao, Yuting Cui, Yunshu Li, Mingtao Zhang, Fei Qin, Gaohong Lyu, et al.

  • Open Access

    Hepatokines and polycystic ovary syndrome: investigating the connection between the hepato-ovarian axis and disorders in glycolipid metabolism in PCOS: a narrative review

    by Rui Zhu, Xinzhe Wang, Jingyun Ma, Xiuwen Shi, Yizhu Zhang, Jing Jin, Huifang Zhou

    Polycystic ovary syndrome (PCOS) is a prevalent endocrine and reproductive disorder affecting 11-13% of women worldwide. It is defined by key clinical signs like elevated androgen levels and infrequent ovulation. PCOS, the most common endocrine cause of infertility in women of reproductive age, is often linked to insulin resistance, obesity, and other metabolic issues. It is closely associated with imbalances in the metabolism of glucose and lipids. Crucially, PCOS interacts with disorders of glucose and lipid metabolism. These metabolic disorders are the main signs of PCOS and can further aggravate the condition. As a vital metabolic organ, the liver produces a range of functional secretory factors known as hepatokines, which are crucial for metabolic regulation. These hepatokines circulate and exert a “Distant crosstalk” effect, influencing processes like glucose uptake, fatty acid breakdown, liver glucose production, inflammation, and various other functions in peripheral tissues. A recent connection between PCOS and nonalcoholic fatty liver disease (NAFLD) has been established, with the hepato-ovarian axis hypothesis considered a possible mechanism. As a result, the liver plays a key role in PCOS and is closely linked to the metabolic disorders involving glycolipids that are often seen with the condition. This review presents an in-depth overview of hepatokines that affect PCOS and its associated glycolipid metabolic disorders, providing key insights into the hepato-ovarian axis.

  • Open Access

    A pharmacological rat model of recurrent pelvic pain exhibiting hyperalgesia and depression-like behaviors

    by Xiaotian Yang, Yajie Qin, Qi Zhao, Huiijin Zhao, Yinyin Ding, Bei Liu, Huifang Zhou

  • Open Access

    Causal associations between sleep disorders and endometriosis: A Mendelian randomization analysis

    by Xiaotian Yang, Yajie Qin, Huijin Zhao, Yuru Zhou, Huifang Zhou

    Evidence have indicated a correlation between sleep disorders and endometriosis, but the causal relationship remains uncertain. This study utilized Mendelian randomization (MR) approach to investigate the causal associations between sleep disorders and endometriosis. We conducted bidirectional 2-sample MR using inverse variance weighting as the primary analysis to assess forward and reverse causality. Multivariable Mendelian randomization were also utilized to adjust for confounders, reducing pleiotropy and residual confounding. Univariable MR analysis demonstrated a positive causal effect of insomnia on endometriosis (inverse variance weighting odds ratio: 2.021, 95% confidence interval: 1.280–3.192, P = .003). Multivariable Mendelian randomization analysis further confirmed that the robustness of the causal association between insomnia and endometriosis after adjusting for key confounders, such as body mass index, alcohol intake, smoking, and depression. However, no causal associations were detected between endometriosis and other sleep-related traits, including chronotype, sleep duration, daytime napping, and daytime sleepiness. This MR study gave novel genetic evidence supporting insomnia as an independent risk factor for endometriosis. These findings highlight the need for greater attention to endometriosis-related sleep disorders in both clinical practice and medical research.


  • Sequential therapy for infertility in women with polycystic ovary syndrome and luteal phase defects by Yangxin Dianji decoction and Nuangong Tiaojing decoction: a real-world study.

    by Jiang Xiaoyue, Diing Yinyin, Liu Xinyuan, Ruan Fang, Zou Yeting, Hong Yanli, Zhou Huifang

    To evaluate the effectiveness and safety of the sequential therapy in treating infertility with polycystic ovary syndrome (PCOS) and luteal phase defects (LPD) by Yangxin Dianji decoction (, YXDJ-D) and Nuangong Tiaojing decoction (, NGTJ-D). This study was undertaken in the Jiangsu Province Hospital of Chinese Medicine. Altogether 90 eligible patients with PCOS and LPD were assigned to exposed group A (Chinese Medicine therapy, YXDJ-D and NGTJ-D), exposed group B (Chinese Medicine plus Western Medicine therapy), control group (Western Medicine therapy). The exposed group A adopted the sequential therapy that YXDJ-D is taken in the postmenstrual period (follicular phase) and NGTJ-D is taken in premenstrual period (luteal phase). Control group took letrozole, dydrogesterone and was given intramuscular injection of human menopausal gonadotropin, human chorionic gonadotropin. The exposed group B was treated with the above-mentioned therapy project of integrated Chinese Medicine and Western Medicine. This study lasted for 2 courses for 6 months. The primary outcomes were pregnancy rate and early abortion rate. The secondary outcomes were the Traditional Chinese Medicine (TCM) syndrome scores, estrogen (E2) and progesterone (P), endometrial volume (EV), vascularity index (VI), flow index (FI) and vascularization flow index (VFI). These outcomes will be assessed at baseline and post-intervention. The pregnancy rates of the exposed group A and B were higher than the control group (60.00% vs 60.00% vs 53.33%), while early abortion rates of exposed groups A and B were lower than the control group (33.33% vs 16.67% vs 43.75%, P > 0.05). Total efficacy rates in exposed group A and B were better than the control group (93.30% vs 93.30% vs 53.30%, P < 0.01). TCM symptom scores and endometrial receptivity indexes (EV, FI, VFI) were significantly lower in exposed groups compared to the control group (P < 0.05). P increase in exposed group B was superior to the other two groups (P < 0.01). No noticeable abnormalities in safety indicators in the three groups. The sequential therapy of YXDJ-D and NGTJ-D can effectively increase pregnancy rate, reduce the early abortion rate and alleviate the clinical symptoms of infertility in patients with PCOS and LPD by improving luteal function and promoting the endometrial receptivity.

  • Open Access

    Wenjing Zhitong Decoction Alleviates Primary Dysmenorrhea Mediated by Pain Sensitization Via the ERα‐BDNF Signaling Pathway

    by Yajie Qin, Xiaotian Yang, Xingran Tang, Huijin Zhao, Huifang Zhou

    Background: Wen‐Jing‐Zhi‐Tong decoction (WJZTD) is a traditional Chinese medicine herbal decoction that has demonstrated clinical efficacy in treating primary dysmenorrhea (PDM) over decades. However, the underlying therapeutic mechanism of WJZTD requires further clarification. Objective: This study aims to explore and elucidate the therapeutic mechanism of WJZTD in treating PDM through metabolomics, integrated network pharmacology, as well as in vitro and in vivo experiments. Methods: A PDM rat model was established by estradiol benzoate and oxytocin for 3 consecutive estrous cycles, and then WJZTD treatment was administered for 3 consecutive estrous cycles. To evaluate the therapeutic effect of WJZTD on PDM, behavioral tests, histological analysis, and evaluation of serum prostaglandins (PGs) were performed. Moreover, immunofluorescence and Western blot analysis were carried out in dorsal root ganglion (DRG) tissues to explore the role of WJZTD in reducing pain sensitivity. Metabolomics and integrated pharmacology were utilized to identify potential bioactive targets, which were then validated through in vitro experiments. Results: WJZTD significantly reduces pain sensitivity in PDM rats, treating the condition effectively by decreasing brain‐derived neurotrophic factor (BDNF) protein expression, c‐Fos‐positive neurons in DRG, and serum prostaglandin PGF2α (PGF2α) levels. A nontargeted metabolic analysis identified 11 differential metabolites, suggesting ESR1 (estrogen receptor α, ERα) as a potential target. In vitro experiments confirmed WJZTD’s efficacy in treating PDM through regulating the ERα/BDNF signaling pathway. Conclusion: WJZTD decreases the excitability of DRG neurons in rats with PDM through the ERα/BDNF pathway, which enhances pain sensitization and contributes to reducing dysmenorrhea.


  • Open Access

    Meta-analysis and network pharmacology studies of the clinical efficacy of Guizhi Fuling capsules/pills combined with dienogest in treating endometriosis

    by Yajie Qin, Xiaotian Yang, Qi Zhao, Xingran Tang, Huijin Zhao, Yang Jiao, Huifang Zhou

    Background: Endometriosis (EMs) is a common chronic inflammatory gynecological disease that belongs to the classification of Traditional Chinese Medicine Syndromes “Zheng Jia,” and the classic Chinese formula Guizhi Fuling (GZFL) demonstrates significant clinical efficacy in the treatment of this condition. This study aims to investigate GZFL’s effect and potential mechanism in EMs. Methods: The search reviewed randomized controlled trials in 7 databases from inception to 2024, assessed quality with the Cochrane tool, and analyzed data with STATA 15 by 2 reviewers. In the network pharmacology study, we searched and screened the components and targets of GZFL, subsequently compared these targets to EMs targets, and used bioinformatics techniques to analyze and explore their potential interactions. Results: Nine randomized controlled trials involving 897 participants were analyzed. Meta-analysis showed that GZFL combined with dienogest significantly enhanced the clinical effectiveness rate (odds ratio = 2.404, 95% confidence intervals [CI], 1.868 to 3.093; P < .001). Specifically, combination therapy with GZFL reduced serum carbohydrate antigen 125 (standardized mean differences [SMD] = −1.65, 95% CI = −2.13 to −1.17, P < .001), estradiol (SMD = −1.54, 95% CI = −1.89 to −1.19, P = .003), matrix metalloproteinases (SMD = −2.636, 95% CI = −2.993 to −2.279, P < .001), pain scores (SMD = −0.88, 95% CI = −1.11 to −0.67, P < .001) and the diameter of ectopic cysts (SMD = −1.7, 95% CI = −2.42 to −0.98, P < .001). Network pharmacology analysis identified 136 components and 145 common targets, focusing on interleukin-6, cellular tumor antigen p53, epidermal growth factor receptor, estrogen receptor alpha, Cyclooxygenase-2, and matrix metalloproteinases-9. Gene ontology and Kyoto Encyclopedia of Genes and Genomes analyses suggested GZFL modulates hormone receptors and inflammatory responses in EMs treatment. Conclusion: In conclusion, GZFL combination treatment could increase the clinical effectiveness rate of EMs patients, and reduce the serum level of carbohydrate antigen 125, estradiol, matrix metalloproteinases, pain scores, and the diameter of the ectopic cyst. The potential mechanism might be linked to the modulation of hormone receptors and inflammation.


  • Open Access

    Efficacy of platelet-rich plasma in the treatment of thin endometrium: a meta-analysis of randomized controlled trials

    by Xinyuan Liu, Chengyu Qian, Xiaoyue Jiang, Yue Zhou, Xue Feng, Yinyin Ding, Jing Jin, Minghui Hu, Weiye Zhou, Bei Liu, et al.

    Thin endometrium (TE) is a common cause of female infertility in clinical practice. Platelet-rich Plasma (PRP) therapy becomes a novel treatment for thin endometrium; however, its clinical application remains controversial. This meta-analysis aims to evaluate the therapeutic effects of intrauterine autologous PRP infusion in women with thin endometrium through relevant randomized controlled trials (RCTs). We systematically searched studies published in English from inception until June 2024 in databases such as PubMed, The Cochrane Library, Embase, Web of Science, and MEDLINE. Search terms included “Platelet-Rich Plasma,” “thin endometrium,” “endometrial thickness,” “infertility,” “pregnancy,” “reproduction,” and “adverse reactions”. RCTs identified through the search were subjected to systematic review and meta-analysis, and data were analyzed using fixed-effects or random-effects models based on heterogeneity. Eight RCTs involving 678 patients with thin endometrium were included. Patients receiving PRP infusion demonstrated significantly superior outcomes compared to the control group in endometrial thickness (MD: 1.23, 95%CI: 0.87 to 1.59, P = 0.000), clinical pregnancy rate (RR: 2.04, 95%CI: 1.52 to 2.76, P = 0.000), live birth rate (RR: 2.46; 95%CI: 1.57 to 3.85, P = 0.000), cycle cancellation rate (RR: 0.46, 95%CI: 0.23 to 0.93, P = 0.000), and embryo implantation rate (RR: 2.71; 95%CI: 1.91 to 3.84, P = 0.000). There were no statistically significance in spontaneous abortion rate (RR: 0.85, 95%CI: 0.40 to 1.78, P = 0.659), chemical pregnancy rate (RR: 1.84, 95%CI: 0.72 to 4.72, P = 0.204) and endometrial vascular improvement rate (RR: 1.10; 95%CI: 0.89 to 1.38, P = 0.367) between the two groups. The limitations of this study includes that, we only included single lauguage for literature research, the sample size and heterogeneity which could cause criteria bias. Intrauterine PRP infusion may be an effective and safe treatment for women with thin endometrium. Further high-quality, large-sample, randomized controlled trials are needed to validate the reliability of our results. The review protocol is registered on PROSPERO with registration number CRD42023490421, and no modifications were made to the information provided at registration.


  • Open Access

    Genetic insights of blood lipid metabolites on polycystic ovary syndrome risk: a bidirectional two-sample Mendelian randomization study

    by Xinzhe Wang, Huawei Han, Xiuwen Shi, Xiaping Nie, Rui Zhu, Jing Jin, Huifang Zhou

    Background: Pathologically, metabolic disorder plays a crucial role in polycystic ovarian syndrome (PCOS). However, there is no conclusive evidence lipid metabolite levels to PCOS risk.Methods: In this study, genome-wide association study (GWAS) genetic data for 122 lipid metabolites were used to assign instrumental variables (IVs). PCOS GWAS were derived from a large-scale meta-analysis of 10,074 PCOS cases and 103,164 controls. An inverse variance weighted (IVW) analysis was the primary methodology used for Mendelian randomization (MR). For sensitivity analyses, Cochran Q test, MR-Egger intercept, MR-PRESSO, leave-one-out analysis,and Steiger test were performed. Furthermore, we conducted replication analysis, meta-analysis, and metabolic pathway analysis. Lastly, reverse MR analysis was used to determine whether the onset of PCOS affected lipid metabolites.Results: This study detected the blood lipid metabolites and potential metabolic pathways that have a genetic association with PCOS onset. After IVW, sensitivity analyses, replication and meta-analysis, two pathogenic lipid metabolites of PCOS were finally identified: Hexadecanedioate (OR=1.85,95%CI=1.27–2.70, P=0.001) and Dihomo-linolenate (OR=2.45,95%CI=1.30–4.59, P=0.005). Besides, It was found that PCOS may be mediated by unsaturated fatty acid biosynthesis and primary bile acid biosynthesis metabolic pathways. Reverse MR analysis showed the causal association between PCOS and 2-tetradecenoyl carnitine at the genetic level (OR=1.025, 95% CI=1.003–1.048, P=0.026).Conclusion: Genetic evidence suggests a causal relationship between hexadecanedioate and dihomo-linolenate and the risk of PCOS. These compounds could potentially serve as metabolic biomarkers for screening PCOS and selecting drug targets. The identification of these metabolic pathways is valuable in guiding the exploration of the pathological mechanisms of PCOS, although further studies are necessary for confirmation.


  • Open Access

    CT‐based radiomics prediction of CXCL13 expression in ovarian cancer

    by Wenting Xu, Chengyi Zhu, Dan Ji, Haiqing Qian, Lingli Shi, Xuping Mao, Huifang Zhou, Lihong Wang

    BackgroundOvarian cancer, the most common malignancy in the female reproductive system, and patients tend to be at middle and advanced clinical stages when diagnosed. Therefore, early detection and early diagnosis have important clinical significance for the treatment of ovarian cancer patients. CXCL13, a chemokine with the ligands CXCR3 and CXCR5, is involved in the tumor metastasis process.PurposeThis study aimed to predict mRNA expression of CXCL13 in ovarian cancer tissues noninvasively.MethodsMedical imaging data and transcriptomic sequencing data of the 343 ovarian cancer patients were downloaded from the TCIA and TCGA databases, respectively. Seventy-six radiomics features were extracted from the CT data. Seven features were selected for model construction by using logistic regression. Accuracy, specificity, sensitivity, positive predictive value, and negative predictive value were used to evaluate the radiomics model.ResultsHigh CXCL13 expression was found to be a significant protective factor for OS [HR (95% CI) = 0.755 (0.622-0.916), p = 0.004]. There was a significant positive correlation between CXCL13 and the degree of eosinophil infiltration. A calibration curve and the Hosmer-Lemeshow goodness-of-fit test showed that the prediction probability of the radiomics prediction model for high expression of CXCL13 was consistent with the true value. The AUC value of the nomogram model's ability to predict OS (12 months) was 0.758. The calibration plot and DCA both showed high clinical applicability for the nomogram model.ConclusionCXCL13 is a candidate predictive biomarker for OC and correlates with the degree of plasma cell and eosinophil infiltration.